Vitamin D3 and Blood Sugar
Vitamin D is the best worked example in nutrition of a gap between epidemiology and trials. The observational association with insulin resistance and diabetes risk is strong, consistent and biologically plausible. The randomised trials that tested whether supplementing changes anything have been far less impressive.
Evidence tier 2. Correct a deficiency; do not expect a treatment.
Table of Contents
The D2d Trial
Pittas and colleagues' D2d trial, published in the New England Journal of Medicine in 2019, is the trial this question deserved. It randomised 2,423 adults at high risk of type 2 diabetes to 4,000 IU of vitamin D3 daily or placebo, and followed them a median of 2.5 years.
The supplementation worked as chemistry: mean serum 25-hydroxyvitamin D rose from 27.7 to 54.3 ng/mL in the treatment group while placebo stayed flat. The outcome did not follow. Diabetes occurred in 293 vitamin D participants and 323 on placebo — a hazard ratio of 0.88 (95% CI 0.75 to 1.04; P = 0.12), which does not reach statistical significance.
Note the direction: 0.88 is a 12% reduction and the confidence interval only barely crosses 1.0. This is not a flat null so much as a small effect the trial was not powered to confirm. But it is emphatically not the effect the observational literature implied, and the crucial design detail is in the paper's own conclusion — participants were not selected for vitamin D insufficiency. Most were already replete.
Repletion Again
That design point is the same one that governs magnesium and zinc on this site, and it is the single most useful idea for reading nutrient trials: giving a nutrient to people who already have enough of it mostly tests nothing.
Recent work has pushed at exactly this. Dawson-Hughes and colleagues' 2026 analysis in JAMA Network Open examined vitamin D receptor polymorphisms within D2d and found that participants carrying particular ApaI alleles showed no response to supplementation at all — which, if it replicates, means the average was diluted not only by baseline status but by genotype. Amrein's 2026 mini-review in Metabolism is a good short summary of where the field now stands.
What to Actually Do
- Test rather than guess. Serum 25-hydroxyvitamin D is a reliable, inexpensive measure of status, which is not true of most nutrients on this page.
- Correct a genuine deficiency. There are good reasons to do that independent of blood sugar — bone, muscle and immune function — and it is the part supported by evidence.
- Do not take it as a diabetes intervention. The largest trial designed to answer that question did not find one.
- More is not better. Vitamin D is fat-soluble and accumulates; very high sustained doses cause hypercalcaemia.
Cautions
- It lowers blood glucose, and so does your medication. The effects add. With insulin or a sulfonylurea this is a hypoglycemia risk, and dose changes belong with the prescriber — see hypoglycemia awareness and prevention.
- Toxicity is real at sustained very high doses — hypercalcaemia, kidney stones, vascular calcification. Vitamin D is fat-soluble and accumulates, unlike the water-soluble entries on this page.
- Caution in sarcoidosis and other granulomatous disease, where vitamin D metabolism is dysregulated and ordinary doses can cause hypercalcaemia.
- Measure, do not assume. Adding a supplement without measuring means you learn about an interaction from a symptom rather than from a number.
Key Research Papers
Every DOI below was checked against Crossref and the abstract read for support before it was listed.
- Pittas AG, Dawson-Hughes B, Sheehan P, et al. Vitamin D Supplementation and Prevention of Type 2 Diabetes. New England Journal of Medicine, 2019;381(6):520–530. The D2d trial; hazard ratio 0.88, P = 0.12.
- Dawson-Hughes B, et al. Vitamin D Receptor Polymorphisms and the Effect of Vitamin D Supplementation on Diabetes Risk Among Adults With Prediabetes. JAMA Network Open, 2026;9(4):e267332.
- Amrein K. Vitamin D for the prevention of type 2 diabetes: evidence and implications. Metabolism, 2026;178:156566.